Experimental cell therapy tested in patients with advanced blood cancer
NCT ID NCT06304636
Summary
This early-stage study tested the safety of Descartes-15, a personalized cell therapy for multiple myeloma patients whose cancer returned or didn't respond to standard treatments. Researchers collected patients' own immune cells, engineered them to target cancer, and reinfused them to assess safety and early signs of effectiveness. The trial was terminated early after enrolling only 4 participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY MULTIPLE MYELOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Center for Cancer and Blood Disorders (AON)
Bethesda, Maryland, 20817, United States
Conditions
Explore the condition pages connected to this study.